生命科学资讯

Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance

Stay Ahead of the Game With Agilent (A) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance

Stay Ahead of the Game With Agilent (A) Q1 Earnings: Wall Street's Insights on Key Metrics - Nasdaq

Agilent Technologies Stock: Analyst Estimates & Ratings - Barchart.com

Agilent Technologies Stock: Analyst Estimates & Ratings - Yahoo Finance

Agilent Technologies Shares: Expert Predictions and Evaluations - Bitget

Ventana Companion Diagnostics Market is Going to Boom | Agilent - openPR.com

Agilent Technologies (A) Valuation Check After FDA Expansion Of Keytruda Companion Diagnostic - simplywall.st

Agilent Technologies (A) Stock Analysis: Unpacking A 34.86% Potential Upside For Investors - DirectorsTalk Interviews

Agilent Technologies Stock: Quiet Rally, Hard Questions – Is The Lab Giant Still A Buy After Its C - AD HOC NEWS

The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News - simplywall.st

Agilent Technologies, Inc. $A Shares Sold by ING Groep NV - MarketBeat

Assetmark Inc. Boosts Position in Agilent Technologies, Inc. $A - MarketBeat

The Bull Case For Agilent Technologies (A) Could Change Following New PD-L1 Test Approval And Dividend News - Sahm

BofA Maintains Hold Rating on Agilent Technologies (A) After Q2 Report - MSN

Agilent Technologies, Inc.'s (NYSE:A) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance

Agilent Technologies, Inc. $A Shares Sold by Rhumbline Advisers - MarketBeat

FDA Ovarian Cancer Nod Puts Focus On Agilent Valuation And Momentum - simplywall.st

Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat